Article Figures & Data
Figures
- Figure 1.
Changes in Pittsburgh Sleep Quality Index (PSQI) scores (A) and Epworth Sleepiness Scale (ESS) scores (B) in 15 patients with RA who received 6 monthly infusions of tocilizumab 8 mg/kg for active disease. Box plots show median values and 25th–75th quantiles. Dots represent outlier values. P values denote significance by linear mixed models.
Tables
- Table 1.
Changes in scores of disease activity by DAS28-ESR, functional status and disability by Health Assessment Questionnaire (HAQ-DI), and fatigue by FACIT-Fatigue Scale (FFS) in 15 patients with active rheumatoid arthritis from baseline through 6 months of treatment with tocilizumab (8 mg/kg). Data are mean ± SD.
Baseline 1st Month 2nd Month 3rd Month 6th Month p* DAS28 5.77 ± 1.2 4.38 ± 0.88 3.6 ± 0.97 2.7 ± 0.88 2.5 ± 0.9 < 0.00001 HAQ-DI 1.5 ± 0.8 1.1 ± 0.66 1 ± 0.58 0.9 ± 0.6 0.7 ± 0.6 < 0.00001 FFS 20.3 ± 11 28.3 ± 11.3 33.7 ± 12 36.4 ± 10 38 ± 9.93 < 0.00001 -
↵* Calculated by linear mixed models. DAS28-ESR: 28-joint Disease Activity Score-erythrocyte sedimentation rate; FACIT: Functional Assessment of Chronic Illness Therapy.
-
- Table 2.
Correlation of PSQI and ESS with DAS28-ESR, HAQ-DI, and FFS during tocilizumab treatment. Correlations by Pearson’s coefficient (r) between the individual changes in scores of Pittsburgh Sleep Quality Index (PSQI) and of Epworth Sleepiness Scale (ESS) with the corresponding changes of DAS28-ESR, Health Assessment Questionnaire Disability Index (HAQ-DI), and FACIT-Fatigue Scale (FFS), in 15 tocilizumab-treated patients with rheumatoid arthritis from baseline through 6 months.
DAS28 HAQ-DI FFS PSQI r = 0.37, p = 0.17 r = 0.6, p = 0.02 r = −0.46, p = 0.08 ESS r = −0.01, p = 0.96 r = −0.05, p = 0.86 r = −0.36, p = 0.2 -
DAS28-ESR: 28-joint Disability Activity Score-erythrocyte sedimentation rate; FACIT: Functional Assessment of Chronic Illness Therapy.
-
In this issue
